← All trials
NCT07184827
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 14, 2020
- Primary completion
- Jun 30, 2028
- Completion date
- Jul 31, 2028
- First posted
- Sep 22, 2025
- Last posted
- Sep 22, 2025
- Enrollment
- 348
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- TCM Biotech International Corp.Lead sponsor
- Government of TaiwanOfficial
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.